Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study

JJ Kiladjian, P Zachee, M Hino, F Pane… - The Lancet …, 2020 - thelancet.com
Background Polycythaemia vera is a myeloproliferative neoplasm characterised by
excessive proliferation of erythroid, myeloid, and megakaryocytic components in the bone …
被引用次数：140 相关文章

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study

JJ Kiladjian, P Zachee, M Hino, F Pane, T Masszi… - The Lancet …, 2020 - Elsevier
Background Polycythaemia vera is a myeloproliferative neoplasm characterised by
excessive proliferation of erythroid, myeloid, and megakaryocytic components in the bone …

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study

JJ Kiladjian, P Zachee, M Hino, F Pane… - THE LANCET …, 2020 - iris.unina.it
Background: Polycythaemia vera is a myeloproliferative neoplasm characterised by
excessive proliferation of erythroid, myeloid, and megakaryocytic components in the bone …

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study

JJ Kiladjian, P Zachee, M Hino… - The Lancet …, 2020 - mdanderson.elsevierpure.com
Background: Polycythaemia vera is a myeloproliferative neoplasm characterised by
excessive proliferation of erythroid, myeloid, and megakaryocytic components in the bone …

[引用][C] Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study

JJ Kiladjian, P Zachee, M Hino, F Pane… - The Lancet …, 2020 - cir.nii.ac.jp
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia
vera (RESPONSE): 5-year follow up of a phase 3 study | CiNii Research CiNii 国立情報学 …

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study

J Kiladjian, P Zachee, M Hino, F Pane… - THE LANCET …, 2020 - air.unimi.it
Background: Polycythaemia vera is a myeloproliferative neoplasm characterised by
excessive proliferation of erythroid, myeloid, and megakaryocytic components in the bone …

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study

JJ Kiladjian, P Zachee, M Hino… - The Lancet …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Polycythaemia vera is a myeloproliferative neoplasm characterised by
excessive proliferation of erythroid, myeloid, and megakaryocytic components in the bone …

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.

JJ Kiladjian, P Zachee, M Hino, F Pane… - The Lancet …, 2020 - europepmc.org
Background Polycythaemia vera is a myeloproliferative neoplasm characterised by
excessive proliferation of erythroid, myeloid, and megakaryocytic components in the bone …

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.

J Kiladjian, P Zachee, M Hino, F Pane… - THE LANCET …, 2020 - iris.unipv.it
We showed that ruxolitinib is a safe and effective long-term treatment option for patients with
polycythaemia vera who are resistant to or intolerant of hydroxyurea. Taken together …

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study

JJ Kiladjian, P Zachee, M Hino, F Pane… - THE LANCET …, 2020 - irinsubria.uninsubria.it
Background: Polycythaemia vera is a myeloproliferative neoplasm characterised by
excessive proliferation of erythroid, myeloid, and megakaryocytic components in the bone …